Search Medical Condition
Please enter condition
Please choose location from dropdown

Okawa-Shi, Japan Clinical Trials

A listing of Okawa-Shi, Japan clinical trials actively recruiting patients volunteers.

RESULTS

Found (39) clinical trials

An Investigational Study of Experimental Medication BMS-986165 in Patients With Moderate to Severe Crohn's Disease

This is an investigational study of experimental medication BMS-986165 in patients with moderate to severe Crohn's Disease, a chronic bowel disease that causes severe inflammation of the digestive tract.

Phase

8.74 miles

Learn More »

Treatment Outcomes in Chronic Hepatitis B Patients on Sequential Therapy With Tenofovir Alafenamide (TAF)

Secondary Objective(s): Describe persistence of ALT (alanine aminotransferase) normalization and/or improvement of ALT levels with TAF as with previous anti-HBV treatment To describe trends in serum creatinine and calculated creatinine clearance as available by local labs. To describe trends in bone mass from baseline to 24 months after switch.

Phase

8.74 miles

Learn More »

The Therapeutic Effects of Peroneal Nerve Functional Electrical Stimulation for Lower Extremity in Patients With Sub-acute Post-stroke Hemiplegia

This study is targeting convalescent patients within 6 months after the onset of initial stroke (cerebral infarction or cerebral hemorrhage) and also observing the foot drop during walking. Some study for the patients after the onset of stroke (over several months) are reported that a case of the efficacy by ...

Phase N/A

9.54 miles

Learn More »

A Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

The study will investigate the antidepressant effects of a range of doses of JNJ-42847922 (seltorexant) (versus placebo), as adjunctive treatment to antidepressant drugs for treatment of MDD, and will assess the safety and tolerability of JNJ-42847922. The study will be conducted in 3 phases: a screening phase (up to 4 ...

Phase

9.66 miles

Learn More »

A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia

The main purpose of this study is to evaluate the efficacy of the study drug known as lanabecestat in participants with mild Alzheimer's disease (AD) dementia.

Phase

9.66 miles

Learn More »

Study Assessing the Safety Tolerability and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With Schizophrenia in 2 Parts (Part 1 and 2).

This multicenter study will be conducted in 2 parts (Part 1 and 2). This is an ascending multiple oral dose, open-label study assessing the safety, tolerability, and pharmacokinetics of SEP-363856 in male and female subjects with schizophrenia. In part 1, subjects will have up to two visits, including a screening ...

Phase

9.66 miles

Learn More »

Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

This randomized, double-blind, placebo-controlled, parallel group study will evaluate the efficacy and safety of gantenerumab versus placebo in participants with early (prodromal to mild) AD. All participants must show evidence of beta-amyloid pathology. Eligible participants will be randomized 1:1 to receive either subcutaneous (SC) injection of gantenerumab or placebo. The ...

Phase

9.66 miles

Learn More »

Study To Evaluate the Efficacy Safety and Tolerability of E2027 in Participants With Dementia With Lewy Bodies

This study will be conducted to compare E2027 to placebo on the cognitive endpoint of Montreal Cognitive Assessment (MoCA) and the global clinical endpoint of Clinician's Interview Based Impression of Change Plus (CIBIC-Plus) Caregiver Input in participants with dementia with Lewy bodies after 12 weeks of treatment.

Phase

9.66 miles

Learn More »

A Study of Molidustat for Maintenance Treatment of Renal Anemia in Non-dialysis Subjects

The purpose of this study is to evaluate the efficacy and safety of molidustat in non-dialysis subjects previously treated with Erythropoiesis-Stimulating Agents (ESAs)

Phase

9.9 miles

Learn More »